BiotechTube
SAB Biotherapeutics

SAB Biotherapeutics

SABS
Sioux Falls, United States
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

SABS · Stock Price

USD 4.09+2.11 (+106.57%)
Market Cap: $269.2M

Historical price data

Overview

SAB Biotherapeutics' mission is to leverage its proprietary DiversitAb™ platform to develop a new class of fully human polyclonal antibody therapeutics. Its key achievement is the creation of a validated, scalable production system using transgenic cattle, which has advanced multiple candidates into clinical trials, including a program for COVID-19. The company's strategy is to clinically validate its platform in autoimmune disease, starting with type 1 diabetes, and expand into other areas of high unmet need where polyclonal antibodies offer a differentiated therapeutic profile. As a public company, SAB is focused on executing its clinical milestones to demonstrate proof-of-concept and attract strategic partnerships.

Autoimmune DiseasesInfectious Diseases

Technology Platform

The DiversitAb™ platform uses genetically engineered transgenic cattle, which carry human antibody genes, to produce fully human, high-diversity, polyclonal antibody therapeutics in response to immunization with specific antigens.

Opportunities

A successful Phase 2 trial for SAB-142 in type 1 diabetes would validate the entire DiversitAb™ platform, unlocking significant value in a multi-billion dollar autoimmune market and enabling expansion into other high-need areas like infectious disease and oncology.
The platform's rapid-response capability also presents a unique opportunity for government partnerships in pandemic preparedness.

Risk Factors

The primary risk is clinical failure of lead candidate SAB-142, which would critically undermine the platform's value proposition.
The company also faces significant financial risk due to its pre-revenue status and low market valuation, which could lead to highly dilutive financing or a cash shortfall before reaching key milestones.

Competitive Landscape

SAB competes against the dominant monoclonal antibody industry by advocating for the superiority of polyclonal responses in complex diseases. Its main competitors are large biopharma companies with mAb portfolios, while its unique transgenic production platform differentiates it from other polyclonal therapy developers.

More companies in United States →